Odyssey Therapeutics, Inc. (NasdaqCM: ODTX)
Salud · Biotecnología · US
18,98 $
-2,01 % hoy · +15,6 % 1 año
Odyssey Therapeutics, Inc. (NasdaqCM: ODTX) opera en la industria de biotecnología dentro del sector salud. Su valor en bolsa es de 909,92 M $ y tiene 100 empleados.
En los últimos doce meses la acción ha subido un 15,6 % y ha cotizado entre 15,10 y 29,05.
Tweenvest puntúa a Odyssey Therapeutics, Inc. en cuatro factores: calidad 44/100, valor 100/100. Su punto más fuerte es valor.
Evolución de la cotización de ODTX
Cifras clave
- Capitalización
- 909,92 M $
- Ingresos (últ. 12 m)
- 0,00 $
- PER
- -5,69
- BPA
- 56,91
- Rent. por dividendo
- —
- Beta (5 años)
- —
- Máximo 52 semanas
- 29,05 $
- Mínimo 52 semanas
- 15,10 $
- Volumen medio (3 m)
- —
- Acciones en circulación
- 47,94 M
- Empleados
- 100
- Próximos resultados
- —
Sobre Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
- ISIN
- US67613T1043
- Fundada en
- 2021
- Cotiza desde
- 8 may 2026
- Bolsa
- Nasdaq Capital Market
- Divisa
- USD
Otras empresas de biotecnología
| Empresa | Capitalización | Precio | Día |
|---|---|---|---|
| Philogen S.p.A.BIT: PHIL | 924,56 M $ | 20,95 € | +0,24 % |
| Chengdu Kanghua Biological Products Co., Ltd.SZSE: 300841 | 924,51 M $ | 47,49 CN¥ | -3,04 % |
| Bio-Thera Solutions, Ltd.SHSE: 688177 | 921,89 M $ | 14,85 CN¥ | -1,20 % |
| MoonLake ImmunotherapeuticsNasdaqCM: MLTX | 918,30 M $ | 10,79 $ | -4,09 % |
| Aktis Oncology, Inc.NasdaqGS: AKTS | 901,69 M $ | 16,16 $ | -2,77 % |
| Corvus Pharmaceuticals, Inc.NasdaqGM: CRVS | 897,52 M $ | 10,64 $ | +0,19 % |
| MeiraGTx Holdings plcNasdaqGS: MGTX | 897,17 M $ | 9,18 $ | +4,44 % |
| PeptiDream Inc.TSE: 4587 | 879,07 M $ | 1089,00 ¥ | -2,94 % |